Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 285

1.

A Quantitative Study of Empty Baskets in Essential Tremor and Other Motor Neurodegenerative Diseases.

Lee PJ, Kerridge CA, Chatterjee D, Koeppen AH, Faust PL, Louis ED.

J Neuropathol Exp Neurol. 2019 Feb 1;78(2):113-122. doi: 10.1093/jnen/nly114.

PMID:
30590599
2.

[Analysis of SMPD1 gene mutations in Chinese patients with Parkinson's disease].

Song N, Wang W, Chen C, Niu J, Guojin Y, Guo C, Han F.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018 Jun 10;35(3):319-323. doi: 10.3760/cma.j.issn.1003-9406.2018.03.003. Chinese.

PMID:
29896723
3.

Glial loss of the metallo β-lactamase domain containing protein, SWIP-10, induces age- and glutamate-signaling dependent, dopamine neuron degeneration.

Gibson CL, Balbona JT, Niedzwiecki A, Rodriguez P, Nguyen KCQ, Hall DH, Blakely RD.

PLoS Genet. 2018 Mar 28;14(3):e1007269. doi: 10.1371/journal.pgen.1007269. eCollection 2018 Mar.

4.

Rehabilitation program based on sensorimotor recovery improves the static and dynamic balance and modifies the basal ganglia neurochemistry: A pilot 1H-MRS study on Parkinson's disease patients.

Delli Pizzi S, Bellomo RG, Carmignano SM, Ancona E, Franciotti R, Supplizi M, Barassi G, Onofrj M, Bonanni L, Saggini R.

Medicine (Baltimore). 2017 Dec;96(50):e8732. doi: 10.1097/MD.0000000000008732.

5.

Safinamide: a new hope for Parkinson's disease?

Teixeira FG, Gago MF, Marques P, Moreira PS, Magalhães R, Sousa N, Salgado AJ.

Drug Discov Today. 2018 Mar;23(3):736-744. doi: 10.1016/j.drudis.2018.01.033. Epub 2018 Jan 12. Review.

PMID:
29339106
6.

Metals and Parkinson's Disease: Mechanisms and Biochemical Processes.

Bjorklund G, Stejskal V, Urbina MA, Dadar M, Chirumbolo S, Mutter J.

Curr Med Chem. 2018;25(19):2198-2214. doi: 10.2174/0929867325666171129124616. Review.

PMID:
29189118
7.

Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.

Morari M, Brugnoli A, Pisanò CA, Novello S, Caccia C, Melloni E, Padoani G, Vailati S, Sardina M.

J Pharmacol Exp Ther. 2018 Feb;364(2):198-206. doi: 10.1124/jpet.117.245100. Epub 2017 Nov 22.

PMID:
29167350
8.

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease.

Cattaneo C, Müller T, Bonizzoni E, Lazzeri G, Kottakis I, Keywood C.

J Parkinsons Dis. 2017;7(4):629-634. doi: 10.3233/JPD-171143.

9.

A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues.

Moriarty GM, Olson MP, Atieh TB, Janowska MK, Khare SD, Baum J.

J Biol Chem. 2017 Sep 29;292(39):16368-16379. doi: 10.1074/jbc.M117.780528. Epub 2017 Jul 14.

10.

Cell-specific α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonism reveals new insights in the development of parkinson's disease.

Pelosi A.

Mov Disord. 2017 Jul;32(7):994. doi: 10.1002/mds.27071. Epub 2017 Jun 16. Review. No abstract available.

PMID:
28621014
11.

Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.

Müller T.

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):693-699. doi: 10.1080/17425255.2017.1329418. Review.

PMID:
28537214
12.

Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model.

Zhang Y, He X, Meng X, Wu X, Tong H, Zhang X, Qu S.

Cell Death Dis. 2017 Feb 2;8(2):e2574. doi: 10.1038/cddis.2016.454.

13.

Stimulation of synaptoneurosome glutamate release by monomeric and fibrillated α-synuclein.

Sarafian TA, Littlejohn K, Yuan S, Fernandez C, Cilluffo M, Koo BK, Whitelegge JP, Watson JB.

J Neurosci Res. 2017 Sep;95(9):1871-1887. doi: 10.1002/jnr.24024. Epub 2017 Jan 24.

15.

Blunted mGluR Activation Disinhibits Striatopallidal Transmission in Parkinsonian Mice.

Cui Q, Pitt JE, Pamukcu A, Poulin JF, Mabrouk OS, Fiske MP, Fan IB, Augustine EC, Young KA, Kennedy RT, Awatramani R, Chan CS.

Cell Rep. 2016 Nov 22;17(9):2431-2444. doi: 10.1016/j.celrep.2016.10.087.

16.

Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.

Viereckel T, Dumas S, Smith-Anttila CJ, Vlcek B, Bimpisidis Z, Lagerström MC, Konradsson-Geuken Å, Wallén-Mackenzie Å.

Sci Rep. 2016 Oct 20;6:35203. doi: 10.1038/srep35203.

17.

Neuroprotection comparison of chlorogenic acid and its metabolites against mechanistically distinct cell death-inducing agents in cultured cerebellar granule neurons.

Taram F, Winter AN, Linseman DA.

Brain Res. 2016 Oct 1;1648(Pt A):69-80. doi: 10.1016/j.brainres.2016.07.028. Epub 2016 Jul 18.

PMID:
27444557
18.

Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.

Niswender CM, Jones CK, Lin X, Bubser M, Thompson Gray A, Blobaum AL, Engers DW, Rodriguez AL, Loch MT, Daniels JS, Lindsley CW, Hopkins CR, Javitch JA, Conn PJ.

ACS Chem Neurosci. 2016 Sep 21;7(9):1201-11. doi: 10.1021/acschemneuro.6b00036. Epub 2016 Aug 5.

19.

Nondopaminergic treatments for Parkinson's disease: current and future prospects.

Freitas ME, Fox SH.

Neurodegener Dis Manag. 2016 Jun;6(3):249-68. doi: 10.2217/nmt-2016-0005. Epub 2016 May 27. Review.

20.

Modulation of Corpus Striatal Neurochemistry by Astrocytes and Vasoactive Intestinal Peptide (VIP) in Parkinsonian Rats.

Yelkenli İH, Ulupinar E, Korkmaz OT, Şener E, Kuş G, Filiz Z, Tunçel N.

J Mol Neurosci. 2016 Jun;59(2):280-9. doi: 10.1007/s12031-016-0757-0. Epub 2016 Apr 26.

PMID:
27115671

Supplemental Content

Loading ...
Support Center